Nature Communications (Jun 2021)

A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry

  • Yanwen Chen,
  • Travis B. Lear,
  • John W. Evankovich,
  • Mads B. Larsen,
  • Bo Lin,
  • Irene Alfaras,
  • Jason R. Kennerdell,
  • Laura Salminen,
  • Daniel P. Camarco,
  • Karina C. Lockwood,
  • Ferhan Tuncer,
  • Jie Liu,
  • Michael M. Myerburg,
  • John F. McDyer,
  • Yuan Liu,
  • Toren Finkel,
  • Bill B. Chen

DOI
https://doi.org/10.1038/s41467-021-24156-y
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 15

Abstract

Read online

The serine protease TMPRSS2 primes SARS-CoV-2 glycoprotein for cell entry. Here, the authors perform a screen to identify drugs that reduce TMPRSS2 expression and find that halofuginone modulates proteasome-mediated degradation of TMPRSS2 and reduces entry of SARS-CoV-2.